Senolytic Class: FOXO4-DRI vs Navitoclax vs Dasatinib+Quercetin Compared | QSC Research
QSC Research · Published 2025-02-15
The Senolytic Class: FOXO4-DRI vs Navitoclax vs Dasatinib+Quercetin Compared
Senolytics are compounds that selectively clear senescent cells — a therapeutic strategy proposed to address the cellular senescence hallmark of ageing. Three major senolytic classes have emerged: FOXO4-DRI (peptide-based), navitoclax (BCL-2/BCL-XL inhibitor), and dasatinib+quercetin (kinase inhibitor combination). Each has distinct mechanisms, selectivity profiles, and research utility.
What Are Senescent Cells and Why Remove Them?
Senescent cells are cells that have permanently exited the cell cycle (replicative senescence, stress-induced senescence) but resist apoptosis through survival pathways. They secrete a pro-inflammatory cocktail called the SASP (senescence-associated secretory phenotype):
SASP Component
Examples
Downstream consequence
Interleukins
IL-6, IL-1b, IL-8
Chronic inflammaging — promotes senescence in neighbouring cells
Chemokines
CCL2, CXCL1
Immune cell recruitment — macrophage infiltration
Proteases
MMP-3, MMP-9, PAI-1
ECM degradation — tissue dysfunction
Growth factors
HGF, VEGF
Tumour microenvironment support (paradoxical cancer-promoting effect
The bystander effect
Senescent cells spread senescence to adjacent cells via SASP. This paracrine senescence means a small number of senescent cells can drive tissue-wide dysfunction. Selective clearance (senolytics) reduces both the direct burden and the paracrine spreading.
FOXO4-DRI — Peptide Senolytic (QSC Catalog)
FOXO4-DRI (retro-inverso FOXO4-p53 interaction domain inhibitor) is a peptide that disrupts the FOXO4-p53 interaction that keeps senescent cells alive:
Property
FOXO4-DRI
Mechanism
Disrupts FOXO4-p53 nuclear interaction → p53 released → apoptosis in senescent cells
Selectivity basis
FOXO4 nuclear localisation is specific to senescent cells (not quiescent or cycling cells)
CAS
N/A — synthetic retro-inverso peptide
Published data
van Deursen / de Keizer 2017 (Cell) — first in vivo senolytic peptide paper
Key finding
FOXO4-DRI cleared p21-high senescent cells in aged mice; improved physical function, hair density, renal function
QSC supply
Lyophilised research vials ≥99% HPLC — Janoshik COA
Navitoclax and Dasatinib+Quercetin — Small Molecule Senolytics
Partial — also affects platelets (thrombocytopenia)
Moderate — broad kinase inhibition
Platelet toxicity
None reported
Yes — dose-limiting thrombocytopenia
Minimal (quercetin may protect)
In vivo evidence
Aged mouse physical function restoration
Progeroid mouse lifespan extension
Human pilot: 14 days D+Q reduced senescence markers
Research access
QSC catalog (research compound)
Research compound (BCL-2 inhibitor)
Dasatinib (research) + quercetin (supplement)
Research Design for Senolytic Studies
Established senolytic research endpoints:
Endpoint
Method
Target
Senescent cell burden
p21/p16/p53 IHC, SA-b-gal staining
Quantify senescent cell frequency before/after
SASP markers
IL-6/IL-8/MMP-3 ELISA (plasma/tissue)
Functional measure of senescent cell activity
Physical function
Grip strength, rotarod, gait analysis
Functional restoration in aged models
Tissue histology
H&E + fibrosis markers (Masson trichrome)
Structural tissue quality
Apoptosis in senescent cells
Annexin V/PI flow on sorted p21-high cells
Confirms senolytic mechanism vs senomorphic
FOXO4-DRI dosing reference (de Keizer 2017)
FOXO4-DRI 5 mg/kg IP 3 days on / 4 days off × 10 days in aged mice produced significant reductions in p21-high cells, SASP markers, and physical function improvements. This intermittent dosing schedule is the published reference protocol.
❓
Frequently Asked Questions
What is a senolytic?
A senolytic is a compound that selectively induces apoptosis in senescent cells (cells permanently exited from the cell cycle that resist normal apoptosis). Senolytics reduce the senescent cell burden and secondarily reduce SASP (senescence-associated secretory phenotype) — the pro-inflammatory secretome of senescent cells.
How does FOXO4-DRI selectively kill senescent cells?
In senescent cells, FOXO4 accumulates in the nucleus and interacts with p53 — keeping p53 sequestered and preventing it from triggering apoptosis. FOXO4-DRI is a retro-inverso peptide that disrupts this FOXO4-p53 interaction → p53 is released → translocates to cytoplasm → triggers mitochondrial apoptosis pathway. FOXO4 nuclear localisation is specific to senescent cells, not quiescent or cycling cells — providing selectivity.
Is FOXO4-DRI available from QSC?
Yes — QSC supplies FOXO4-DRI as lyophilised research vials, ≥99% HPLC purity, Janoshik COA. See the FOXO4-DRI research hub for full mechanism data, protocols, and study information.
